A Study of the Long-Term Outcomes of HIV-Positive Patients
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Highly active antiretroviral therapy (HAART) often results in short-term benefits for people with HIV in terms of reduced plasma viral levels and increased CD4 cell counts. When used at an early stage of HIV disease, however, the clinical benefit of HAART is uncertain. Many questions still remain regarding the optimal use of antiretroviral therapies, such as the timing of initial antiretroviral therapy and the composition of the best combination regimen to use initially or after virologic failure. Randomized trials of different starting antiretroviral regimens (e.g., FIRST \[CPCRA 058\]), d...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients may be eligible for this study if they:
- • Are 13 years of age or older (consent of parent or guardian required if under the age of 18).
- • Are HIV-positive.
- • Have either: (1) no previous experience with anti-HIV treatment (defined as no previous protease inhibitor or nonnucleoside reverse transcriptase inhibitor use, 1 week or less of lamivudine use, and 4 weeks or less of cumulative nucleoside reverse transcriptase inhibitor use) or (2) current or previous enrollment in a qualifying CPCRA study.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Denver, Colorado, United States
Mill Valley, California, United States
Oakland, California, United States
Oakland, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
San Francisco, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
Farmington, Connecticut, United States
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Baton Rouge, Louisiana, United States
Baton Rouge, Louisiana, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Camden, New Jersey, United States
Hillsborough, New Jersey, United States
Neptune, New Jersey, United States
Newark, New Jersey, United States
Newark, New Jersey, United States
Paterson, New Jersey, United States
Perth Amboy, New Jersey, United States
Randolph, New Jersey, United States
Union, New Jersey, United States
Voorhees, New Jersey, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Salem, Oregon, United States
Salem, Oregon, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Mechanicsville, Virginia, United States
Norfolk, Virginia, United States
Petersburg, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Patients applied
Trial Officials
Jay Kostman
Study Chair
Roberta Luskin-Hawk
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials